IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Howard Hoffman who wrote (1399)	12/10/1997 12:33:00 AM
From: I. Luttichuys	Read Replies (1) of 1762

The potential market is quite large. At least one billion... in the industry parlance, that's what they call a home run. Yes, I believe SK is backing the 2nd generation anti-body because they believe in it. Just trying to make the point that, they were wrong once and could be wrong again. Anyway, if any pharm were to successfully launch an effective RA therapy which interrupts RA disease progression instead of simply relieving pain, that would be one helluva a stock. I would expect that revenues from a market that large would catapult this stock into the triple digits and make for the funding necessary to really get the ball rolling on an already decent pipeline. Problem with previous therapies, is that they do nothing to halt the progression of the disease. The pain is nice to be relieved of but, pain and inflammation relief isn't all... the disease is physically deforming as well and this cannot be stopped by current remedies. I believe what IDEC had worked... problem is, those CD4 counts. The FDA will never let that fly. This one needs to be different. BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next